CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 15 enrolled
Drug / intervention
Methylphenidate extended-release liquid formulationdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02096952
NCT02096952Phase 4Completed
CompareCT.gov

Open-Label Treatment Trial to Assess the Short-Term Tolerability, Safety, and Efficacy of Methylphenidate Hydrochloride Extended-Release Liquid Formulation in High-Functioning Autism Spectrum Disorder Adults With Attention-Deficit/Hyperactivity Disorder

Massachusetts General Hospital·interventional·Posted Mar 26, 2014·Updated Jul 1, 2024

In Brief

A Phase 4 clinical trial evaluating Methylphenidate extended-release liquid formulation for Attention-deficit/Hyperactivity Disorder and Autism Spectrum Disorder. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether methylphenidate hydrochloride extended release liquid formulation is safe and effective in the treatment of attention-deficit/hyperactivity disorder (ADHD) in high-functioning adults with autism spectrum disorders (ASD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 26, 2014
Enrollment StartMay 1, 2014
Primary CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 12.3 years ago

Interventions

Methylphenidate extended-release liquid formulationdrug